BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.
To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.
To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.
Reprints
Cigna Corp. has changed its policy for a new and in-demand medicine for ALS, or amyotrophic lateral sclerosis, deciding not to cover it due to “a lack of clinical efficacy data,” Healthcare Dive reports. The drug Relyvrio, which Cigna called “experimental, investigational or unproven,” was developed by the Massachusetts-based biotechnology company Amylyx Pharmaceuticals and costs $158,000 per year.
1. Biden vetoes bill that would block ESG considerations by pension funds
2. Lawsuit accuses insurers, PBM of colluding to drive up Rx costs
3. Cigna CEO can be deposed in noncompete dispute with CVS: Judge
5. CMS issues guidelines for negotiation on 10 highest-priced drugs
6. Justice Department to end appeal of UnitedHealth, Change Healthcare deal